Join us

Engage with us in a change of paradigm

  • Arrow logo brenus pharma

    Efficient technology

    Anticipates risks of tumor escape
    Answers huge unmet need in solid tumors

  • Arrow logo brenus pharma

    Derisked approach

    2nd generation of innovative immuno-oncology
    FDA Pre-IND passed
    Top scientific leaders on board

  • Arrow logo brenus pharma

    Limitless potential

    IP by design-platform strategy
    Tailored first-in-class drugs design
    Dynamic immuno-oncology market

Key milestones validated

  • Regulatory

    • mCRC preclinical package endorsed by FDA & FAMHP (EMA)
    • STC 1010 FDA pre-IND and 2 SA with EU FAMHP passed
  • Manufacturing

    • Product - GLP, Drugs subsances - GMP
    • Gap Analysis
    • Pre scale-up & Tech transfer - GMP, experienced CDMO
  • IP

    • STC platform design - Granted in Key countries
    • STC-1010 Product - Published
Cells Brenus pharma steps

Competitive advantages

STC Technology overpassing previous challenges in immune oncology

Cells Brenus pharma steps

Brenus Pharma stimulated tumor cell line (STC)

The 2nd generation of an impactful haptenized immunotherapy

  • Largest panel of antigens driven by tumor plasticity
  • No HLA restriction
  • Boosted immunogenicity with maintened safety
  • GMP manufacturing process ready

With the support of

With the support of

  • <strong>DEEPTECH LABEL</strong><br />
by BPI (French Public Investment Bank)
    DEEPTECH LABEL
    by BPI (French Public Investment Bank)
  • <strong>EUROSTARS - ALLOGENIX</strong> project<br />
Brenus Pharma x InSphero AG<br />
Nov 2022 - Nov 2025
    EUROSTARS - ALLOGENIX project
    Brenus Pharma x InSphero AG
    Nov 2022 - Nov 2025

Our awards

  • MATWIN 2021 award
  • Finalist 2022
  • BIOLABS MASTERCLASS
    Boston 2022
  • 2022 PRIX GALIEN USA AWARD NOMINEE
    "Best startup in the Pharmaceutical or Biotech industry"
  • ENRICH IN USA 2022 award